Chemotherapy & Bevacizumab for Human Epidermal Growth Factor Receptor 2 (HER2)/Neu-Negative Stage II/III Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: HER2-negative Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer
Interventions: DRUG: doxorubicin hydrochloride|DRUG: cyclophosphamide|BIOLOGICAL: bevacizumab|DRUG: paclitaxel|DRUG: gemcitabine hydrochloride|OTHER: laboratory biomarker analysis|BIOLOGICAL: pegfilgrastim
Sponsor: University of Nebraska
Collaborators: National Cancer Institute (NCI)